Individual choice of menopausal hormone therapy
- Authors: Ovsyannikova TV1, Kulikov IA2
-
Affiliations:
- People’s Friendship University of Russia
- I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
- Issue: Vol 18, No 4 (2016)
- Pages: 59-62
- Section: Articles
- URL: https://journals.rcsi.science/2079-5831/article/view/28562
- ID: 28562
Cite item
Full Text
Abstract
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
T V Ovsyannikova
People’s Friendship University of Russia
Email: dr.otoma@yandex.ru
д-р мед. наук, проф. каф. акушерства, гинекологии и репродуктивной медицины ФГАОУ ВО РУДН. 117198, Russian Federation, Moscow, ul. Miklukho-Maklaya, d. 6
I A Kulikov
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federationканд. мед. наук, доц. каф. акушерства и гинекологии ИПО ГБОУ ВПО Первый МГМУ им. И.М.Сеченова 119991, Russian Federation, Moscow, ul. Trubetskaya, d. 8, str. 2
References
- http://vz.ru/news/2016/2/11/793605.html
- Менопаузальная гормонотерапия и сохранение здоровья женщин зрелого возраста. Клинические рекомендации. М., 2014.
- Попова С.М., Яник А.А. Проблемы глобального старения населения: анализ документов и стратегии ООН Международное право и международные организации. Int Law Int Organiz 2014; 3: 429-43. doi: 10.7256/2226-6305.2014.3.12857
- Lobo R.A, Davis S.R, De Villiers T.J et al. Prevention of diseases after menopause. Climacteric 2014; 17 (5): 540-56. doi: 10.3109/13697137.2014.933411. Epub 2014 Jun 27.
- http://www.fundshub.ru/
- http://worktips.ru/pochemu-vygodno-brat-na-rabotu-50-letnix/
- http://fevt.ru/load/rabochee_vremja/100-1-0-1495
- http://ecouniver.com/7625-cel-organizacii-rabochego-mesta-zhenshhin.html
- Avis N.E, Crawford S.L, Greendale G. Study of Women's Health Across the Nation. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med 2015; 175 (4): 531-9. doi: 10.1001/jamainternmed.2014.8063.
- Bardel A, Wallander M.A, Wedel H, Svärdsudd K. Age - specific symptom prevalence in women 35-64 years old: a population - based study. BMC Public Health 2009; 9: 37. doi: 10.1186/1471-2458-9-37
- Pinkerton J.V, Abraham L, Bushmakin A.G et al. Relationship between changes in vasomotor symptoms and changes in menopause - specific quality of life and sleep parameters. Menopause 2016; Jul 11. [Epub ahead of print]
- Freeman E.W, Sammel M.D, Sanders R.J. Risk of long - term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort. Menopause 2014; 21 (9): 924-32. doi: 10.1097/GME.0000000000000196
- Hodis H.N, Mack W.J, Henderson V.W.N. ELITE Research Group. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. Engl J Med; 374 (13): 1221-31. doi: 10.1056/NEJMoa1505241
- Abdi F, Mobedi H, Mosaffa N. Hormone Therapy for Relieving Postmenopausal Vasomotor Symptoms: A Systematic. Arch Iran Med 2016; 19 (2): 141-6. DOI: 0161902/AIM.0013
- http://pikabu.ru/story/prichinyi_smerti_naseleniya_v_rf_v_2014_godu_3428488
- Yoon P.W, Bastian B, Anderson R.N et al. Centers for Disease Control and Prevention (CDC). Potentially preventable deaths from the five leading causes of death - United States, 2008-2010. MMWR Morb Mortal Wkly Rep 2014; 63 (17): 369-74.
- Benkhadra K, Mohammed K, Al Nofal A. et al. Menopausal Hormone Therapy and Mortality: A Systematic Review and Meta - Analysis. J Clin Endocrinol Metab 2015; 100 (11): 4021-8. doi: 10.1210/jc.2015-2238.
- Mikkola T.S, Tuomikoski P, Lyytinen H. Estradiol - based postmenopausal hormone therapy and risk of cardiovascular and all - cause mortality. Menopaus 2015; 22 (9): 976-83. doi: 10.1097/GME.0000000000000450
- Сметник В.П., Балан В.Е., Зайдиева Я.З. и др. Ведение женщин с сердечно - сосудистым риском в пери - и постменопаузе. Рос. кардиологический журн. 2008; 4: 40-57.
- Collins P, Webb C.M1, de Villiers T.J еt al. Cardiovascular risk assessment in women - an update. Climacteric 2016; 19 (4): 329-36. doi: 10.1080/13697137.2016.1198574. Epub 2016 Jun 21
- Gass M.L, Maki P.M, Shifren J.L et al. NAMS supports judicious use of systemic hormone therapy for women aged 65 years and older. Menopause 2015; 22 (7): 685-6. doi: 10.1097/GME.0000000000000491
- Schürmann R, Holler T, Benda N. Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double - blind, randomized, placebo - controlled study of the safety and efficacy of three dose regimens. Climacteric 2004; 7 (2): 189-96.
- Gambacciani M, Rosano G, Cappagli B. Clinical and metabolic effects of drospirenone - estradiol in menopausal women: a prospective study. Climacteric 2011; 14 (1): 18-24. doi: 10.3109/13697137.2010.520099. Epub 2010 Oct 27.
- AGOS Practice BULLETTIN No 141: Management Of Menopausal Symptoms. Obstet Gynecol 2014; 123-202-216.
- Инструкция по применению препарата Анжелик Микро. http://www.rlsnet.ru/tn_index_id_80329.htm
- Archer D.F, Schmelter Th, Schaefers M et al. A randomized, double - blind, placebo - controlled study of the lowest effective dose of drospirenone with 17β-estradiol for moderate to severe vasomotor symptoms in postmenopausal women. Menopause 2014; 21 ( 3): 227-35.doi: 10.1097/GME.0b013e31829c1431
- Genazzani A.R, Schmelter T, Schaefers M. One - year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17β-estradiol in postmenopausal women. Climacteric 2013; 16: 490-8. doi: 10.1056/NEJMoa1505241
Supplementary files
